Studies involving disease:Malaria

Study ID Study Title Species Institute
ST000414Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of actionPlasmodiumMonash Institute of Pharmaceutical Sciences
ST000441Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target PathwaysPlasmodiumPennsylvania State University
ST000546Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant PlasmodiumPlasmodiumMonash University
ST000578Experiment HuA: Metabolomics of plasma samples from humans infected with Plasmodium vivax strain.HumanEmory University
ST000592Uninfected Macaca mulatta exposed to pyrimethamine to produce and integrate clinical, hematological, and omics control measures.MonkeyEmory University
ST000599Metabolomics measures of Macaca mulatta infected with Plasmodium coatneyi Hackeri strainMonkeyEmory University
ST001033Determination of mode of action of anti-malalrial drugs using untargeted metabolomicsPlasmodiumMonash University
ST001149Plasmodium Niemann-Pick Type C1-Related Protein is a Druggable Target Required for Parasite Membrane HomeostasisPlasmodiumPennsylvania State University
ST001175Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparumPlasmodiumMonash University
ST001188P. falciparum infected erythrocytesPlasmodiumUniversity of Melbourne
ST001201Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasitesHumanMonash University
ST001201Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasitesPlasmodiumMonash University
ST001202Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasitesHumanMonash University
ST001202Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasitesPlasmodiumMonash University
ST001204Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasitesHumanMonash University
ST001204Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasitesPlasmodiumMonash University
ST001205Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasitesHumanMonash University
ST001205Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasitesPlasmodiumMonash University
ST001232Combining stage - specificity and metabolomic profiling to advance drug discovery for malariaPlasmodiumPennsylvania State University
ST001238P falciparum asexual metabolomics following drug treatment (part-I)PlasmodiumPennsylvania State University
ST001239NMR assignment of synthetic pantothenamides (part-II)Synthetic compoundsPennsylvania State University
ST001279K13 mutations driving artemisinin resistance rewrite Plasmodium falciparum’s programmed intra-erythrocytic development and transform mitochondrial physiologyPlasmodiumPennsylvania State University
ST001315Retargeting azithromycin-like compounds as antimalarials with dual modalityPlasmodiumMonash University
ST001384Plasmodium falciparum increased time in circulation underlies persistent asymptomatic infection in the dry seasonHumanPennsylvania State University
ST001516Identification of distinct metabolic perturbations and associated immunomodulatory events during intra-erythrocytic development stage of pediatric Plasmodium falciparum malaria (part-II)HumanNew York University Abu Dhabi
ST001517Identification of distinct metabolic perturbations and associated immunomodulatory events during intra-erythrocytic development stage of pediatric Plasmodium falciparum malaria (part-III)HumanNew York University Abu Dhabi
ST001652Atypical Molecular Basis for Drug Resistance to Mitochondrial AQ: A Function Inhibitors in Plasmodium falciparumMalariaU.S. Food & Drug Administration

Return to search page
  logo